综合/综合Ⅱ 公 司 研 复星国际（00656.HK） 瘦身+健体，全球化+多产业协同共促成长 究 2024年04月03日 ——港股公司信息更新报告 投资评级：买入（维持） 初敏（分析师） chumin@kysec.cn 日期 2024/4/2 证 书编号：S0790522080008  “瘦身”强化流动性管理，“健体”提高产业运营能力 港 当前股价(港元) 4.260 据复星公众号 4月 2 日推送，21 世纪经济报道记者独家对话徐晓亮，徐晓亮认 股 一年最高最低(港元) 5.930/3.930 公 为：复星国际“瘦身”是为“健体”，全球化运营大有可为。2023年复星国际实 司 总市值(亿港元) 348.34 现营收1982亿元/yoy+8.6%，产业运营利润49亿元/yoy+20%，2023年末合并报 信 流通市值(亿港元) 348.34 息 表有息债务2119.2亿元，同比下降150亿元，杠杆率50.4%/yoy-2.9pct。标普全 总股本(亿股) 81.77 更 球将复星评级展望由“负面”调升为“稳定”。公司通过持续“瘦身”强化流动 新 流通港股(亿股) 81.77 性管理，提升产业运营和轻资产能 ...

Financial Performance - The company achieved a total revenue of RMB 1982 billion in 2023, representing an 8.6% year-on-year increase [1] - Net profit attributable to the parent company reached RMB 13.8 billion, showing significant growth compared to the previous year [1] - The company's debt structure improved, with interest-bearing debt decreasing by RMB 15 billion and the total debt-to-capital ratio dropping to 50.4% [1] Innovation and R&D - The company invested RMB 7.4 billion in technological innovation in 2023, a 14% year-on-year increase, exceeding revenue growth [1] - Intuitive Fosun successfully launched the first domestically produced Da Vinci surgical robot in November 2023 [1] - Fosun Rui Zhi Xing optimized its front-fusion algorithm and implemented a satellite architecture multi-chip radar system, achieving high scalability in radar algorithms and front-fusion solutions on high-performance SoC domain control platforms [1] Global Operations - Overseas revenue reached RMB 89.2 billion in 2023, accounting for 45% of total revenue and showing a 6% year-on-year increase [1] - The company has established industrial layouts in over 35 countries and regions, developing a "global organization + local operation" model [1] - The company's global strategy focuses on creating global capabilities, integrating global R&D and markets [1] Cultural Influence - The Yuyuan Lantern Festival, a representative Chinese cultural event, was successfully held in Paris, France, attracting nearly 200,000 local visitors [2] - The event served as the opening ceremony for the 60th anniversary of Sino-French diplomatic relations and the Sino-French Cultural Tourism Year [2] Strategic Focus - The company has shifted its industrial operation strategy from global exploration to deep mining in established industries, aiming for stable profit growth [2] - The company remains committed to its core philosophy of "rooted in China, serving the world" and continues to focus on creating healthy, happy, and prosperous lives for global families [1][2]

Financial Performance - The company's total revenue for the year ended December 31, 2023, was RMB 198.2 billion, representing an 8.6% increase year-on-year[4]. - Net profit attributable to shareholders reached RMB 1.38 billion, an increase of RMB 2.21 billion compared to the previous year[4]. - The group's operating profit amounted to RMB 4.9 billion, representing a year-on-year increase of 20.4%[25]. - The group's profit attributable to shareholders reached RMB 1,379.1 million, a significant increase of 265.8% compared to a loss of RMB 831.8 million in the previous year[74]. - The total profit for the year ended December 31, 2023, was RMB 5,347,126 thousand, a significant increase from RMB 2,996,562 thousand in 2022, representing an increase of approximately 78.5%[172]. Revenue Contributions - The four core subsidiaries contributed 72% to the overall revenue growth, with Fosun Tourism achieving a revenue of RMB 17.15 billion, up 24.5% year-on-year[4]. - The revenue of the jewelry fashion group under Yuyuan Co. reached RMB 36.7 billion in 2023, representing an 11% year-on-year growth, outperforming the industry average[13]. - Club Med achieved a record revenue of RMB 15.12 billion in 2023, a 19.2% increase compared to 2022, and 118.3% of the 2019 level[14]. - The average occupancy rate of Atlantis Sanya reached 81.9% in 2023, with a significant year-on-year revenue growth of 90.9% to RMB 1.67 billion[14]. - Fosun Tourism's total revenue was RMB 17,151.8 million, a year-on-year increase of 24.5%, with a profit of RMB 307.2 million compared to a loss of RMB 544.9 million in 2022[118]. Debt and Financial Position - The company's total interest-bearing debt decreased by RMB 15 billion to RMB 211.92 billion by the end of 2023, with a debt-to-capital ratio of 50.4%, down 2.9 percentage points from the end of 2022[17]. - Cash and bank balances reached RMB 92.5 billion, indicating a strong financial position[27]. - The average debt cost slightly increased to 5.60%, up 89 basis points from 4.71% in 2022[26]. - The group's total debt to total capital ratio decreased by 2.9 percentage points to 50.4%[27]. - The group has achieved a cash inflow of approximately RMB 40 billion by the end of the reporting period[26]. Innovation and R&D - In 2023, the company invested a total of RMB 7.4 billion in scientific innovation, covering multiple industry sectors with over ten innovation centers[10]. - The company plans to strengthen its research and development investments to seize global development opportunities[68]. - The company is actively exploring cutting-edge technologies such as RNA and gene therapy to boost its innovation capacity[50]. - The health segment emphasizes innovation, internationalization, integration, and intelligence to enhance product and brand strength[49]. - R&D investment totaled RMB 5,937 million, an increase of 0.88% year-on-year, with R&D expenses at RMB 4,346 million, up 1.02%[83]. Market Expansion and Global Operations - Overseas revenue amounted to RMB 89.2 billion, accounting for 45% of total revenue, with a year-on-year growth of 6%[7]. - The company has successfully launched multiple innovative drugs in overseas markets, including the first Chinese independently developed monoclonal antibody approved in over 40 countries[7]. - The company’s subsidiary, Fosun Pharma, received approval for its innovative drug, Hansizhuang®, in Indonesia, marking the first Chinese PD-1 monoclonal antibody approved in Southeast Asia[31]. - Fosun Pharma is expanding its pharmaceutical product distribution in over 40 countries in Africa, with a local manufacturing facility under construction in Côte d'Ivoire[88]. - Gland Pharma has expanded its presence to over 60 countries, focusing on strategic acquisitions and partnerships for growth[53]. Sustainability and ESG - The group has been recognized with an MSCI ESG AA rating for three consecutive years, ranking in the top 6% globally in sustainability assessments[20]. - The company released its first TCFD report in April 2023, demonstrating its commitment to climate action and sustainable financing[45]. - The company committed to achieving carbon peak by 2028 and carbon neutrality by 2050, supporting the Paris Agreement's 1.5°C target[44]. - The company received an ESG rating of 11.7 from Sustainalytics, ranking fourth globally among insurance companies and second in Europe[133]. - The company’s MSCI ESG rating remains at AA, making it the only comprehensive enterprise in Greater China with this rating[47]. Strategic Focus and Business Segments - The company is focusing on core family consumption sectors and has exited non-core assets to strengthen its financial position[5]. - The company aims to create more quality products and services for one billion families globally through its strategic initiatives[6]. - The company aims to enhance its core business focus and improve operational capabilities while gradually exiting non-core industries[68]. - The Happy Sector targets family consumption needs and has built a global happiness ecosystem, with investments in various segments including jewelry, food, and tourism[55]. - The Wealth Sector leverages insurance as a core financial asset, creating a global asset management ecosystem to enhance the company's health, happiness, and intelligent manufacturing sectors[60]. Insurance and Financial Services - The insurance segment reported a revenue of RMB 37,453.6 million, a 5.1% year-over-year decline, but a profit of RMB 790.2 million, a significant increase of 126.6% compared to the previous year[130]. - Fosun Portugal Insurance's total gross premium for 2023 was €5.207 billion, a slight increase of 1.7%, with non-life insurance premiums growing by 10.5% to €2.902 billion[132]. - The international business of Fosun Portugal Insurance saw a 10.6% increase in total premiums, reaching €1,703 million, highlighting the advantages of its international diversification strategy[132]. - Dingrui Reinsurance recorded a net profit of USD 200 million in 2023, a significant recovery from a loss of USD 261 million in 2022, with net asset value increasing from USD 1.12 billion to USD 1.28 billion[137]. - Fosun P&C Life reported total premium income of RMB 4,346 million in 2023, a year-on-year increase of 77.45%, with new single premium growth in agent channels, postal agency channels, and professional agency channels at 23%, 161%, and 222% respectively[138]. Product Development and Launches - The company successfully launched 5 products (19 indications) in mainland China and 2 products in Europe, Australia, and Indonesia, with significant approvals for new indications of its core product Hanshuang®[90]. - Three new products were launched in new regions, including the Soprano Titanium™ platform in North America, Opus in international markets, and Alma Veil™ in North America, enhancing the product portfolio[99]. - The company launched a strategic new product "藏品•舍得 10 年" targeting the RMB 1,000 price segment, enhancing its market positioning[116]. - The company has established a multi-level health and elderly care service brand, Fosun Kangyang, which includes three major brands and focuses on elderly care, rehabilitation, and community health services[54]. - The company aims to enhance its integrated online and offline medical services and expand specialty service capabilities in key economic regions[104].

聚焦發展，穩健升級 2023年上半年，國際政治經濟環境依然複雜多變，國內經濟溫和復甦，面對紛繁複雜的宏觀環境，復星 加快聚焦家庭消費主賽道，專注發展核心優勢產業，整體業務穩健向上。報告期內，本集團實現總收入 人民幣970.6億元，同比增長10.9%；反映企業經營質量的關鍵指標一產業運營利潤達人民幣33.7億元， 同比增長5.5%，若剔除已處置企業（含未交割企業）利潤因素，則同口徑同比強勁提升66%；報告期內歸 屬於母公司股東之淨利潤為人民幣13.6億元。 與此同時，復星持續優化資金和資產結構，加大非戰略非核心資產處置，並積極開拓融資渠道，流動性 保持良好韌性。報告期內，本集團合併報表層面退出項目回籠現金超人民幣200億元；2023年1月，復星 高科成功在國內獲得8家銀行的人民幣120億元銀團貸款，體現了國內銀行對民營企業發展的堅定支持。 在公開市場融資渠道方面，復星高科於2023年1月和7月分別完成人民幣10億元超短期融資券發行。報告 期內，本集團成功跨越公開債務的到期牆，共兌付境內債券人民幣67.3億元及超過美元27億元的境外債 務。截至2023年6月30日止，本集團於一年內已無大額境外債券到期。信用狀況的 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 中期業績公告 （未經審核） 截至 2023 年 6 月 30 日止六個月 財務摘要 截至6月30日止六個月 以人民幣百萬元列示 2023 2022 （重列*） 總收入 97,064.6 87,549.6 健康 23,837.6 23,366.6 快樂 43,001.6 32,065.4 富足 25,435.0 27,629.5 保險 18,442.4 20,547.0 資管 6,992.6 7,082.5 智造 5,460.2 5,127.0 內部抵銷 (669.8) (638.9) 歸屬於母公司股東之利潤/（虧損） 1,359.7 2,282.2 ...

Financial Performance - The profit attributable to shareholders for 2022 was RMB 538.7 million, a significant decrease from RMB 10,084.5 million in 2021[2][8]. - Total revenue for 2022 reached RMB 175,393.4 million, up from RMB 161,291.2 million in 2021, representing a growth of approximately 8.5%[8]. - The group achieved a total revenue of RMB 175.39 billion in 2022, representing an increase of 8.7% year-on-year[10]. - Profit attributable to shareholders of the parent company was RMB 540 million, a significant decrease of 94.7% year-on-year[11]. - The group's operating profit was RMB 7.1 billion, a decrease of 32.9% year-on-year due to the impact of recurring domestic pandemic[29]. - The profit attributable to shareholders was RMB 540 million, down from RMB 1.008 billion in the same period of 2021[29]. - The profit attributable to equity holders of the parent company in 2022 was RMB 538.7 million, down from RMB 10,084.5 million in 2021, representing a decline of approximately 94.67%[186]. - The basic earnings per share for 2022 was RMB 0.06, a significant drop from RMB 1.21 in 2021[186]. Revenue Segmentation - The health segment generated revenue of RMB 48,001.3 million, an increase from RMB 43,979.8 million in the previous year[8]. - The happiness segment reported revenue of RMB 70,739.5 million, compared to RMB 66,898.3 million in 2021, reflecting a growth of about 5.5%[8]. - Overseas revenue reached RMB 77.36 billion in 2022, accounting for 44.1% of total revenue, with a year-on-year growth of 14.3%[15]. - The wealth segment's revenue was RMB 47,722.4 million, reflecting a 9.2% increase year-on-year, with insurance and asset management contributing RMB 32,427.8 million and RMB 15,294.6 million respectively[60]. - The happiness segment's brand consumption and tourism culture revenue accounted for 80% and 20% of its total revenue, respectively[59]. - The wealth segment's insurance and asset management revenues accounted for 68% and 22% of its total revenue, respectively[59]. Investment and Innovation - The group invested RMB 10.4 billion in scientific innovation in 2022, marking a 17% increase year-on-year[5]. - R&D investment reached RMB 10.4 billion, a year-on-year increase of 17%[17]. - The company plans to continue increasing innovation investment and will focus on the quantity and quality of R&D inputs in subsidiary assessments[19]. - The company aims to leverage its global operations and technological innovation to drive sustainable development and fulfill its social responsibilities[58]. - The strategic business segments include new energy materials, electronic chemicals, and biotechnology, focusing on continuous technological innovation and R&D investment[57]. Debt and Financial Strategy - Total debt to total capital ratio was 53.2% as of December 31, 2022, maintaining stability, with cash and bank deposits reaching RMB 100.56 billion[20]. - The company emphasizes a strategy of reducing interest-bearing debt and improving credit ratings as part of its financial strategy[21]. - The total debt for 2022 was RMB 226,919.2 million, a decrease from RMB 237,119.5 million in 2021, with a total debt to total capital ratio of 53.2%[186]. - The interest coverage ratio for 2022 was 3.1 times, down from 4.4 times in 2021, due to a decrease in EBITDA from RMB 42,107.6 million in 2021 to RMB 32,016.9 million in 2022[181]. Market Expansion and Global Operations - The company is focusing on enhancing its global operations and innovation capabilities, with a presence in over 35 countries and regions[4]. - The company aims to deepen its industry operations and enhance vertical integration to create leading enterprises in its advantageous sectors[12]. - The company has signed contracts for non-strategic asset disposals exceeding RMB 40 billion since June 2022, recovering nearly RMB 30 billion in cash flow[3]. - The company secured a loan of up to RMB 12 billion from a consortium of banks, indicating strong confidence in its future growth[11]. ESG and Sustainability - The company aims to achieve carbon peak by 2028 and carbon neutrality by 2050, with an MSCI ESG rating of AA, the only comprehensive enterprise in Greater China with this rating[6]. - The group has achieved a MSCI ESG rating of AA, being the only comprehensive enterprise in Greater China with this rating[24]. - The company has established an ESG board committee and management committee to implement its ESG strategy effectively[39]. - The group plans to enhance its ESG standards through investments, including the acquisition of Bai Zhong Environment, to prepare for carbon peak and carbon neutrality in the steel industry[54]. Consumer Engagement and Digital Transformation - Digital membership increased by 50.8 million, a year-on-year growth of 27%, with over 133 products achieving over 100 million in sales, a 20% increase[22]. - The average occupancy rate of Atlantis Sanya reached 96.0% in the first two months of 2023, with other resorts also achieving over 90% occupancy[13]. - The company emphasizes the importance of consumer confidence in economic growth and aims to provide healthier and happier lifestyles for families globally[12]. - The company is committed to improving its ESG governance, with Yuyuan Group's MSCI ESG rating upgraded from BB to BBB[95]. Product Development and Healthcare - The first PD-1 monoclonal antibody for small cell lung cancer was approved, and the CAR-T cell therapy product has benefited nearly 300 patients[18]. - The group has developed a new oral COVID-19 drug, Azvudine, which has been included in national treatment guidelines and medical insurance[26]. - The health sector focuses on innovative drug development and medical devices, responding to the increasing demand for quality healthcare products and services[42]. - Fosun Pharma achieved revenue of RMB 43,811 million, representing a year-on-year growth of 12.73%, and net profit attributable to shareholders (excluding non-recurring items) increased by 18.37% to RMB 3,879 million[71]. Corporate Governance - The board has appointed at least one-third independent non-executive directors in compliance with listing rules[192]. - The company has mechanisms in place to ensure the independence of directors, including annual confirmations of independence and the ability to seek independent professional advice[193]. - The board encourages all directors to express independent opinions and constructive questions during meetings[193]. - The company has established governance policies and procedures, ensuring compliance with legal and regulatory requirements[199].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 年度業績公告 截至2022年12月31日止年度 財務摘要 截至 12 月 31 日止年度 以人民幣百萬元列示 2022 2021 (重列*) 收入 175,393.4 161,291.2 健康 48,001.3 43,979.8 快樂 70,739.5 66,898.3 富足 47,722.4 43,699.4 保險 32,427.8 32,149.3 資管 15,294.6 11,550.1 智造 10,355.6 7,736.9 內部抵銷 (1,425.4) (1,023.2) 歸屬於母公司股東之利潤/（虧損） 538.7 10,084.5 ...

Financial Performance - In 2021, Fosun International achieved a revenue of RMB 161.29 billion, representing an 18.0% year-on-year increase[10]. - The profit attributable to shareholders reached RMB 10.09 billion, up 26.1% compared to the previous year[10]. - The operating profit from core industries was RMB 10.59 billion, reflecting a 30.3% increase year-on-year[10]. - The basic and diluted earnings per share were both RMB 1.21, compared to RMB 0.94 in the previous year[7]. - The company declared a dividend of HKD 0.30 per share, up from HKD 0.22 in the previous year[7]. - The company's total debt to total capital ratio is 53.8%, showing a slight year-on-year decrease, with an average debt cost at a historical low of 4.6%[18]. - The company's total debt rose to RMB 237,119.5 million in 2021, with a debt-to-capital ratio of 53.8%[138]. - The average cost of debt for 2021 was 4.55%, a decrease of 0.25 percentage points compared to the previous year[120]. - The profit attributable to equity holders of the parent company was RMB 10,089.9 million in 2021, a decrease of 26.5% compared to RMB 13,161.3 million in 2017[138]. Segment Performance - The health segment generated revenue of RMB 43.98 billion, a 27.1% increase from RMB 34.61 billion in 2020[7]. - The happiness segment reported revenue of RMB 66.90 billion, up 19.0% from RMB 56.02 billion in 2020[7]. - The wealth segment's revenue increased to RMB 43.70 billion, a slight rise of 2.8% from RMB 42.52 billion in 2020[7]. - The health segment reported revenue of RMB 43,979.8 million for the year ended December 31, 2021, representing a year-on-year growth of 27.1%[46]. - The happiness segment's revenue was RMB 66,898.3 million, making up 41.2% of total revenue, reflecting a 19.4% increase year-on-year[37]. - The wealth segment's profit was RMB 5,160.1 million, which accounted for 50.7% of total profit, with a year-on-year increase of 13.5%[38]. Research and Development - Research and development investment totaled RMB 8.9 billion, with over 1,500 patents obtained and more than 500 projects under research[5]. - The company invested approximately RMB 8.9 billion in technology and innovation capabilities, including both expensed and capitalized research investments[21]. - Research and development expenses totaled RMB 4,975 million, up 24.28% compared to the previous year, with R&D costs specifically increasing by 37.17% to RMB 3,834 million[47]. Global Expansion and Acquisitions - The establishment of the Overseas Operations Committee in 2021 aims to accelerate Fosun's global organizational evolution and promote exponential growth in global business[13]. - The acquisition of Bankhaus Lampe, a significant private bank in Germany, was completed in September 2021, showcasing Fosun's strong local execution capabilities despite pandemic challenges[13]. - The company has expanded its global operations, including the acquisition of Bankhaus Lampe in Germany to enhance business collaboration in mainland China and Hong Kong[20]. - The company has opened new resorts in Seychelles, Lijiang, and Quebec, marking its expansion in the North American ski business[20]. ESG and Social Responsibility - The company's ESG rating was upgraded to AA by MSCI in December 2021, recognizing its performance in ESG management[18]. - The company actively disposes of non-core assets while pursuing equity financing to enhance asset valuation transparency[18]. - The company participated in various public welfare activities, donating RMB 50 million in response to the severe flooding in Henan[24]. - The company has been involved in the "Malaria-Free World" project for over 15 years, supplying over 200 million doses of innovative drugs to international markets[24]. - The company aims to enhance its ESG standards while seizing development opportunities along the Belt and Road Initiative[33]. Operational Efficiency and Cost Management - Fosun's global procurement reduced costs by RMB 2 billion, with direct procurement rate increasing by 9% and centralized procurement rate rising by 6%[16]. - The company successfully raised a total of RMB 33.19 billion through various financing activities, including approximately USD 1.57 billion in offshore bonds[23]. - The company has implemented a strategic management system to improve decision-making efficiency and organizational agility[193]. - The company has successfully reduced operational costs by 5%, improving overall profitability margins[173]. Talent Management and Employee Engagement - The company emphasizes a talent-first approach, with a focus on attracting industry leaders and high-potential talent across various sectors[193]. - The company has launched multiple talent development programs, including leadership development projects and management training, to cultivate core talent at various levels[198]. - The company has established a systematic talent inventory and succession planning system, focusing on attracting and operating key talents[194]. - The company has implemented various care plans for different employee groups, enhancing employee experience and engagement[197]. Future Outlook and Strategic Initiatives - The company provided a positive outlook for the next quarter, projecting a revenue growth of 10% to 12%[174]. - New product launches are expected to contribute an additional 1 billion in revenue over the next year[176]. - The company is considering strategic acquisitions to enhance its portfolio, targeting companies with a combined revenue of 2 billion[176]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[140].

FOSUN 复星 復 星 國 際 有 限 公 司 FOSUN INTERNATIONAL LIMITED (在香港註冊成立之有限公司) (股份代號 : 00656) 2020 ion& Win 歸屬於母公司股東 之利潤為 人民幣 百萬元 8,017.9 創‧贏 2020年，可能是復星最具挑戰的一年，但也是最好的一年。疫情發生後，我們在全球抗疫中所形成的戰時 機制和戰鬥精神，驅動全年業務迸發出十足的韌勁。疫情的洗禮也使我們長期積累的「產業運營+產業投 資」、FC2M、全球化、科技創新等核心能力得到了全面升級，進化出了一個更強大的復星。 今年復星年報的主題是「創‧贏」。「創」是指復星一直重視創新，我們認識到只有加大創新研發投入，才 可打造全球一流產品。也正是我們長期以來對產業科創的堅定投入和積累，以及憑藉復星多元化及全球化的 業務組合、「產業運營+產業投資」的發展模式、從抗疫期間所延續下來的戰時狀態，才使得我們有效抵禦 了外部環境的衝擊，推動集團業績展現出十足的韌勁，與各利益相關方實現共「贏」和多「贏」的局面。 2021年是復星「蛻變」的新起點。面對產業互聯網時代所蘊含的巨大機遇，我們在原先聚焦打造好產品的基 礎 ...